Logo image of AARD

AARDVARK THERAPEUTICS INC (AARD) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AARD - US0029421007 - Common Stock

9.5 USD
+0.13 (+1.39%)
Last: 11/24/2025, 8:00:00 PM
Fundamental Rating

3

Taking everything into account, AARD scores 3 out of 10 in our fundamental rating. AARD was compared to 192 industry peers in the Pharmaceuticals industry. While AARD has a great health rating, there are worries on its profitability. AARD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AARD has reported negative net income.
In the past year AARD has reported a negative cash flow from operations.
AARD Yearly Net Income VS EBIT VS OCF VS FCFAARD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

With a Return On Assets value of -24.84%, AARD perfoms like the industry average, outperforming 55.21% of the companies in the same industry.
AARD has a better Return On Equity (-26.76%) than 61.46% of its industry peers.
Industry RankSector Rank
ROA -24.84%
ROE -26.76%
ROIC N/A
ROA(3y)-58.64%
ROA(5y)N/A
ROE(3y)-64.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AARD Yearly ROA, ROE, ROICAARD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AARD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AARD Yearly Profit, Operating, Gross MarginsAARD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

9

2. Health

2.1 Basic Checks

AARD has about the same amout of shares outstanding than it did 1 year ago.
AARD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AARD Yearly Shares OutstandingAARD Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M 20M
AARD Yearly Total Debt VS Total AssetsAARD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 20M 40M 60M

2.2 Solvency

AARD has an Altman-Z score of 11.13. This indicates that AARD is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 11.13, AARD belongs to the top of the industry, outperforming 83.85% of the companies in the same industry.
AARD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.13
ROIC/WACCN/A
WACCN/A
AARD Yearly LT Debt VS Equity VS FCFAARD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

AARD has a Current Ratio of 14.04. This indicates that AARD is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 14.04, AARD belongs to the best of the industry, outperforming 84.38% of the companies in the same industry.
A Quick Ratio of 14.04 indicates that AARD has no problem at all paying its short term obligations.
The Quick ratio of AARD (14.04) is better than 84.90% of its industry peers.
Industry RankSector Rank
Current Ratio 14.04
Quick Ratio 14.04
AARD Yearly Current Assets VS Current LiabilitesAARD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for AARD have decreased strongly by -185.61% in the last year.
EPS 1Y (TTM)-185.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-85.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 4.88% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-212.68%
EPS Next 2Y-89.39%
EPS Next 3Y-54.67%
EPS Next 5Y4.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AARD Yearly Revenue VS EstimatesAARD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
AARD Yearly EPS VS EstimatesAARD Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AARD. In the last year negative earnings were reported.
Also next year AARD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AARD Price Earnings VS Forward Price EarningsAARD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AARD Per share dataAARD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

AARD's earnings are expected to decrease with -54.67% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-89.39%
EPS Next 3Y-54.67%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AARD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AARDVARK THERAPEUTICS INC

NASDAQ:AARD (11/24/2025, 8:00:00 PM)

9.5

+0.13 (+1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-30 2026-03-30
Inst Owners50.6%
Inst Owner Change6.17%
Ins Owners14.55%
Ins Owner Change3.37%
Market Cap206.15M
Revenue(TTM)N/A
Net Income(TTM)-36.64M
Analysts84.62
Price Target31.24 (228.84%)
Short Float %4.54%
Short Ratio4.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.61%
Min EPS beat(2)-7.84%
Max EPS beat(2)-3.38%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.06%
PT rev (3m)-6.63%
EPS NQ rev (1m)0.8%
EPS NQ rev (3m)-9.02%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.83%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.51
P/tB 1.51
EV/EBITDA N/A
EPS(TTM)-1.97
EYN/A
EPS(NY)-3.45
Fwd EYN/A
FCF(TTM)-1.52
FCFYN/A
OCF(TTM)-1.52
OCFYN/A
SpS0
BVpS6.31
TBVpS6.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -24.84%
ROE -26.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.64%
ROA(5y)N/A
ROE(3y)-64.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -566.67%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.04
Quick Ratio 14.04
Altman-Z 11.13
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-185.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-85.7%
EPS Next Y-212.68%
EPS Next 2Y-89.39%
EPS Next 3Y-54.67%
EPS Next 5Y4.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-207.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-153.85%
EBIT Next 3Y-64.19%
EBIT Next 5YN/A
FCF growth 1Y-212.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-210.56%
OCF growth 3YN/A
OCF growth 5YN/A

AARDVARK THERAPEUTICS INC / AARD FAQ

What is the fundamental rating for AARD stock?

ChartMill assigns a fundamental rating of 3 / 10 to AARD.


What is the valuation status for AARD stock?

ChartMill assigns a valuation rating of 0 / 10 to AARDVARK THERAPEUTICS INC (AARD). This can be considered as Overvalued.


How profitable is AARDVARK THERAPEUTICS INC (AARD) stock?

AARDVARK THERAPEUTICS INC (AARD) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for AARD stock?

The Earnings per Share (EPS) of AARDVARK THERAPEUTICS INC (AARD) is expected to decline by -212.68% in the next year.